医学
神经纤维瘤病
塞鲁美替尼
临床试验
神经纤维瘤病
靶向治疗
丛状神经纤维瘤
皮肤病科
病理
MEK抑制剂
周围神经鞘恶性肿瘤
纤维神经瘤
癌症研究
肿瘤科
2型神经纤维瘤病
神经鞘肿瘤
周围神经
神经纤维蛋白1
化疗
活检
内科学
周围神经病变
作者
Aimee A. Sato,Dawn Earl,Stephanie E. Wallace
摘要
Neurofibromatosis type 1 (NF1) is a progressive multisystem condition that is characterized by a wide range of clinical manifestations and clinical variability. Individuals with NF1 can be significantly impacted by NF1-related complications, and targeted therapies are emerging. Currently, MEK inhibitors selumetinib and mirdametinib are the only FDA-approved targeted therapies for NF1-related symptomatic or progressive, inoperable plexiform neurofibromas. Several additional MEK inhibitors are being investigated in clinical trials for the treatment of plexiform neurofibromas. Additional therapies are currently under investigation for the treatment of malignant peripheral nerve sheath tumors, low-grade gliomas, skeletal manifestations, cutaneous neurofibromas, and other NF1-related complications.
科研通智能强力驱动
Strongly Powered by AbleSci AI